Preliminary experience with paclitaxel in advanced bladder cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Urothelial cancer is a significant health concern, often requiring systemic chemotherapy for advanced stages.
• Limited effective first-line treatment options exist for advanced urothelial cancer.
• Paclitaxel is a chemotherapy agent with known activity in various solid tumors.

Purpose of the Study:

• To evaluate the efficacy and safety of single-agent paclitaxel in patients with advanced urothelial cancer.
• To determine objective response rates and toxicity profiles of paclitaxel in this patient population.
• To establish the potential role of paclitaxel in the treatment of urothelial carcinoma.

Main Methods:

• A phase II Eastern Cooperative Oncology Group trial was conducted.
• Twenty-six patients with advanced urothelial cancer, with no prior systemic chemotherapy, were enrolled.
• Paclitaxel was administered at 250 mg/m2 via 24-hour continuous infusion with prophylactic granulocyte colony-stimulating factor.

Main Results:

• An objective response rate of 42% (11 of 26 patients) was observed, including complete and partial responses.
• Grade 3 or 4 neutropenia occurred in 23% of patients, with only two cases of febrile neutropenia.
• Non-hematologic toxicities included neurologic toxicity, mucositis, and diarrhea, which were generally manageable.

Conclusions:

• Single-agent paclitaxel demonstrates significant activity in advanced urothelial cancer.
• Paclitaxel is a viable treatment option with a manageable toxicity profile for this patient group.
• Future research should explore paclitaxel in combination regimens and as salvage therapy.